Education
About Us
Working with TipRanks
Follow Us
BiomX (PHGE)
:PHGE
Top Page
BiomX
(NYSE MKT:PHGE)45Neutral
Positive Factors
Financial Performance
BiomX announced 3Q24 financial results, posting EPS of $0.31 compared with an estimate of ($0.06).
Mergers and Acquisitions
The recent merger with Adaptive Phage Therapy expanded BiomX’s pipeline with BX211, a phage-based therapy developed to treat DFO patients infected with S. aureus.
Negative Factors
Operational Challenges
Due to manufacturing delays, the topline data from the BX004 study are now expected by 1H26.
BiomX (PHGE) vs. S&P 500 (SPY)
Market Cap
$14.97M
Dividend YieldN/A
Average Volume (3M)92.82K
Price to Earnings (P/E)―
Beta (1Y)1.74
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees71
SectorHealthcare
Sector Strength74
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.35
Shares Outstanding24,996,054
10 Day Avg. Volume180,828
30 Day Avg. Volume92,817
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
BiomX Business Overview & Revenue Model
Company DescriptionBiomX Inc. is a clinical-stage microbiome company that develops natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, including inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. The company leverages its proprietary drug discovery platform to identify and develop customized phage therapies that address unmet medical needs in the fields of infectious diseases and cancer.
How the Company Makes MoneyBiomX generates revenue primarily through collaborative research and development agreements, grant funding, and potential future licensing deals. The company engages in partnerships with pharmaceutical companies and research institutions to co-develop therapies, which may involve upfront payments, milestone payments, and royalties on future sales. Additionally, BiomX aims to commercialize its proprietary therapies, which could become significant revenue streams once approved and brought to market. The company also benefits from government and private grants to support its research activities.
BiomX Financial Statement Overview
Summary
BiomX faces significant financial challenges, characterized by negative revenue, poor margins, and cash flow deficits. Although the balance sheet shows some equity strength, the company's high debt levels and cash flow issues suggest a pressing need for improved operational efficiency and revenue generation to enhance financial health.Income Statement
BiomX has significant challenges in its income statement. The company is experiencing negative revenue growth, as revenue remains negative with no clear upward trend. The margins are deeply negative, including gross profit margin, EBIT margin, and net profit margin, reflecting substantial operational losses, which is concerning for profitability and stability.25
Negative
Balance Sheet
The balance sheet shows a moderate level of stability. The equity ratio is relatively healthy, indicating that the company is not overly leveraged. However, the debt-to-equity ratio is somewhat high, which could pose risks if profitability does not improve. Positive stockholders' equity is a strength, providing some buffer against liabilities.45
Neutral
Cash Flow
Cash flow analysis reveals poor performance with negative free cash flow and operating cash flow, indicating liquidity concerns. The company struggles to generate cash from operations, which could hinder its ability to finance activities without external funding. Free cash flow growth remains negative, highlighting cash management issues.30
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| -259.00K | -357.00K | -134.00K | 0.00 | 0.00 | 0.00 | Gross Profit |
| -3.05M | -1.23M | -2.65M | -2.56M | -2.18M | -404.52K | EBIT |
| -32.39M | -27.68M | -27.22M | 35.46M | -30.26M | -22.21M | EBITDA |
| -4.45M | -22.82M | -23.65M | -32.89M | -27.90M | -20.18M | Net Income Common Stockholders |
| -27.99M | -26.17M | -28.32M | -36.23M | -29.91M | -18.92M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 896.73K | 15.86M | 33.33M | 62.10M | 56.33M | 82.26M | Total Assets |
| 70.92M | 25.03M | 45.53M | 77.99M | 70.36M | 92.12M | Total Debt |
| 500.00K | 15.09M | 19.36M | 20.02M | 5.89M | 1.23M | Net Debt |
| -396.73K | -772.00K | -11.97M | -42.08M | -30.58M | -71.03M | Total Liabilities |
| 521.37K | 21.95M | 24.49M | 30.45M | 12.89M | 7.67M | Stockholders Equity |
| 70.40M | 3.08M | 21.04M | 47.53M | 57.47M | 84.46M |
| Cash Flow | Free Cash Flow | ||||
| -36.94M | -21.34M | -29.20M | -31.25M | -25.46M | -18.89M | Operating Cash Flow |
| -36.93M | -21.29M | -29.09M | -27.57M | -24.45M | -17.58M | Investing Cash Flow |
| 770.00K | 1.95M | -2.11M | 16.17M | -10.86M | 19.74M | Financing Cash Flow |
| 37.45M | 2.90M | 292.00K | 37.28M | 134.00K | 61.55M |
BiomX Technical Analysis
Negative
0.60
Price Trends
0.77
Negative
0.75
Negative
1.51
Negative
Market Momentum
-0.05
Positive
35.79
Neutral
7.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHGE, the sentiment is Negative. The current price of 0.6 is below the 20-day moving average (MA) of 0.81, below the 50-day MA of 0.77, and below the 200-day MA of 1.51, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 35.79 is Neutral, neither overbought nor oversold. The STOCH value of 7.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PHGE.
BiomX Risk Analysis
BiomX disclosed 72 risk factors in its most recent earnings report. BiomX reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BiomX Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
49 Neutral | $7.05B | 0.34 | -55.09% | 2.46% | 25.27% | -3.43% | |
49 Neutral | $3.91B | ― | -19.20% | ― | -89.95% | -123.71% | |
48 Neutral | $244.69M | ― | 322.49% | ― | -21.66% | 22.53% | |
45 Neutral | $14.97M | ― | -72.95% | ― | ― | ― | |
42 Neutral | $38.38M | ― | -270.20% | ― | 144.50% | -141.91% | |
42 Neutral | $129.44M | ― | -98.10% | ― | 150.95% | 5.48% | |
39 Underperform | $979.28M | ― | -54.00% | ― | 59.55% | 3.09% |
* Healthcare Sector Average
Performance Comparison
PHGE
BiomX
0.59
-3.11
-84.05%
BLUE
Bluebird Bio
3.94
-22.96
-85.35%
EDIT
Editas Medicine
1.56
-7.05
-81.88%
NTLA
Intellia Therapeutics
9.46
-18.32
-65.95%
CRSP
Crispr Therapeutics AG
43.34
-31.96
-42.44%
FHTX
Foghorn Therapeutics
4.40
-2.14
-32.72%
BiomX Earnings Call Summary
Earnings Call Date: Nov 14, 2024 | % Change Since: -16.67% | Next Earnings Date: Mar 26, 2025
Earnings Call Sentiment Positive
The earnings call presented a mix of positive developments and challenges. Key achievements include completing patient enrollment for a crucial trial and securing additional funding, along with a net income turnaround. However, manufacturing delays and increased expenses pose challenges. Despite these issues, the company's positive clinical results and financial runway provide a strong outlook.Highlights
Completion of Patient Enrollment for BX211 Phase II Trial
BiomX completed patient enrollment for the BX211 Phase II trial, with top line results expected in the first quarter of 2025. This trial focuses on diabetic foot osteomyelitis (DFO) associated with Staphylococcus aureus.
Additional Funding from U.S. Defense Health Agency
The U.S. Defense Health Agency provided additional funding this past quarter, bringing total nondilutive funding for the DFO trial to $36.8 million.
Positive Clinical Data for BX004
Positive safety and efficacy results from the BX004 Phase Ib/IIa trial were presented at key scientific conferences, showing a significant portion of patients achieved sputum culture conversion to negative for Pseudomonas aeruginosa.
Net Income Turnaround
BiomX reported a net income of $9.6 million for the third quarter of 2024, compared to a net loss of $7.9 million in the same period of 2023, primarily due to noncash income from warrant revaluation.
Sufficient Cash Runway
BiomX's cash reserves are sufficient to fund operations into the fourth quarter of 2025, following a $50 million private placement financing in March 2024.
Lowlights
Manufacturing Delays for BX004
BiomX experienced manufacturing delays for BX004, resulting in a shift of the Phase IIb study's top line results to the first half of 2026.
Increase in R&D and Administrative Expenses
Research and development expenses increased to $7.3 million in Q3 2024 from $5.6 million in Q3 2023. General and administrative expenses rose to $3.2 million from $2.2 million for the same periods, largely due to the Adaptive Phage Therapeutics acquisition.
Goodwill Impairment Expense
A goodwill impairment expense of $801,000 was recognized in Q3 2024, related to the Adaptive Phage Therapeutics acquisition.
Company Guidance
During the BiomX Q3 2024 earnings call, the company provided several key metrics and updates regarding their clinical pipeline and financial status. BiomX announced the completion of patient enrollment for the Phase II trial of BX211 targeting diabetic foot osteomyelitis (DFO), with top-line results expected in Q1 2025. They highlighted that the U.S. Defense Health Agency has contributed $36.8 million in funding for this trial. The company also addressed a manufacturing delay for BX004, a treatment for chronic lung infections in cystic fibrosis patients, which pushed the Phase IIb study results to the first half of 2026. Financially, BiomX reported a cash balance of $24.7 million as of September 30, 2024, and a net income of $9.6 million for the quarter, reflecting non-cash income from warrant revaluation. The company also noted increased R&D expenses due to trial preparations and a goodwill impairment expense of $801,000 related to their March 2024 acquisition of Adaptive Phage Therapeutics.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.